![]() |
|
|
Vol. 282, Issue 2, 727-733, 1997
Departments of
Physiology and Pharmacology, The forced swimming test (FST) predicts the efficacy of clinically
effective antidepressants. In the present study, using the FST we
examined the antidepressant potential of three novel tropane analogs:
8-methyl-2
-propanoyl-3
-(4-(1-methylethyl)- phenyl)-8-azabicyclo[3.2.1] (WF-31) and 2
-propanoyl-3
-(4(1-methylethyl)phenyl)-8-azabicyclo[3.2.1]octane (WF-50), selective
inhibitors of serotonin uptake, and
8-methyl-2
-propanoyl-3
-(4-(1-methylphenyl)-8-azabicyclo[3.2.1] octane (PTT, WF-11), a selective inhibitor of dopamine uptake. Fluoxetine and GBR 12909 were used as controls for selective inhibitors of serotonin and dopamine, respectively. Drugs were administered three
times in a 24-hr period between pretest and test sessions. Intraperitoneal administration of WF-31 (0.1-10.0 mg/kg), WF-50 (0.3-10.0 mg/kg) and fluoxetine (0.3-10.0 mg/kg) dose-dependently decreased immobility while increasing swimming. In contrast, WF-11 (0.3-3.0 mg/kg) dose-dependently decreased immobility and
increased both swimming and climbing, whereas GBR 12909 (3.0-30.0
mg/kg) decreased immobility, increased climbing but did not affect
swimming. In a separate experiment, WF-11 (1.0 mg/kg) increased
locomotor activity, whereas a higher dose of WF-11 (3.0 mg/kg) and
GBR-12909 (30.0 mg/kg) produced stereotypic behaviors, suggesting that
the effects in the FST may have been attributable to increases in general activity. However, the effects of WF-11 on swimming in the FST
indicate that WF-11 produces antidepressant-like effects in addition to
motor stimulation. These results confirm previous results that
behavioral patterns manifested in the FST are characteristic of
specific monoamine uptake inhibitors. In addition, these results demonstrate that WF-31 and WF-50 produce behavioral patterns similar to
fluoxetine in the FST without accompanying decreases in motor activity,
suggesting a potential antidepressant action. Based on comparisons with
fluoxetine, the data suggest WF-31 and WF-50 may be therapeutically
useful as potential antidepressant medications.
Copyright © by The American Society for Pharmacology and Experimental Therapeutics